Date: May 10, 2021
Time: 7am PDT / 10am EDT / 3pm BST / 4pm CEST
Custom webcast sponsor retains sole responsibility for content.
Predictive genomics is the culmination of the Human Genome Project—using genetic data to help predict many common disease risks and drug responses. In the series of 3 webinars, this first webcast will demonstrate the power of predictive genomics to transform health care from a reactive to a preemptive role, helping to improve outcomes and optimize costs.
Predictive genomics helps identify disease risks with polygenic risk scores (PRSs) and manage adverse drug responses (ADRs) with pharmacogenomics (PGx). The understanding of PRS and PGx will significantly change personalized and population health management in the future.
Dr. Aarno Palotie of the Institute for Molecular Medicine Finland (FIMM), the University of Helsinki, and the Broad Institute of MIT and Harvard, will share the emerging vision of preemptive health care enabled by genomics, expanding on the value of PRS and PGx in disease risk stratification and medication management, with examples from his group’s work
Dr. Andres Metspalu, of the Estonian Genome Center at the University of Tartu, the Institute of Genomics, and the Estonian biobank, will speak about the future of preemptive health care, highlighting why population-based biobanks are important for building a predictive genomics program, and showcasing examples from his work with a number of major European initiatives.
You will learn:
- What are PRS and PGx, and how are they paving ways to enable personalized and population health?
- How predictive genomics is changing healthcare from reactive to preemptive, improving outcomes and lowering costs
- Why it is critical to capture target population diversity in building meaningful predictive genomics models and why biobanks play an important role
Unable to join the live event? Watch on-demand. Register now to ensure that you receive information on how to gain access after the live event.
This webcast has been produced by Thermo Fisher Scientific, who retains sole responsibility for content. About this content.
Dr. Aarno Palotie, Institute for Molecular Medicine Finland (FIMM) and The Broad
Prof. Aarno Palotie, MD, Ph.D., focuses on improving the understanding of the genetic mechanisms underlying common diseases, by leveraging the data from the unique Finnish population. His research interest also encompasses understanding genetics of neurological, neurodevelopmental, and neuropsychiatric traits. He has been engaged with many key initiatives such as Finngen study and UK10K project, with the vision to construct a large genome data resource that facilitates the development of strong genome medicine programs.
Dr. Andres Metspalu, Estonian Genome Center, University of Tartu
Prof. Andres Metspalu, MD, Ph.D., leads research in human genomics, genetics of complex diseases and population-based biobanks, and application of precision medicine in health care. He has published more than 500 papers and chapters in international peer-reviewed journals and books. He founded the Molecular Diagnostic Center of the Tartu University Hospital and is one of the founders and directors of the P3G Consortium of Biobanks (Montreal) and BBMRI-ERIC (a European research infrastructure for biobanking).
Moderator: Sarah Hiddleston, Science Journalist
Sarah Hiddleston is freelance journalist working with Nature Research for Nature Middle East since 2015. Previously, Sarah worked for a decade in Madras (Chennai), India, specialising in health, pharmaceutical and environmental stories. Sarah holds an MA in Investigative Journalism from City University London, an MSc in Political Theory from the London School of Economics, and an undergraduate degree in History from the University of Cambridge, UK.